| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 12 May 2026 | 5 May 2026 |
| Pfizer Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/05/2026 ,inter alia, to consider and approve This is to inform that a meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, May 12, 2026 inter alia, to consider, approve and take on record the financial results of the Company for the quarter and year ended March 31, 2026 and to consider recommendation of dividend, if any, for the financial year ended March 31, 2026. Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you the outcome of meeting of Board of Directors of the Company held today, i.e., May 12, 2026. (As per BSE Announcement dated on: 12.05.2026) | ||
| Board Meeting | 9 Feb 2026 | 30 Jan 2026 |
| Pfizer Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2026 inter alia to consider and approve This is to inform that a meeting of the Board of Directors of the Company is scheduled to be held on Monday February 9 2026 inter alia to consider approve and take on record the Unaudited Financial Results of the Company for the quarter and nine months ended December 31 2025. Pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2025, which were approved by the Board of Directors of the Company at their Meeting held today i.e., February 9, 2026, that commenced at 3.00 p.m. and concluded at 4.45 p.m. (As per BSE Announcement dated on: 09.02.2026) | ||
| Board Meeting | 12 Nov 2025 | 3 Nov 2025 |
| Pfizer Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2025 inter alia to consider and approve This is to inform that a meeting of the Board of Directors of the Company is scheduled to be held on Wednesday November 12 2025 inter alia to consider approve and take on record the Unaudited Financial Results of the Company for the quarter and half year ended September 30 2025. Pursuant to Regulations 30 and 33 of the Listing Regulations, we submit herewith the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2025, which were inter alia approved by the Board of Directors of the Company at their Meeting held today i.e., November 12, 2025, that commenced at 2.00 p.m. and concluded at 3.15 p.m (As Per Bse Announcement dated on 12/11/2025) | ||
| Board Meeting | 13 Aug 2025 | 7 Aug 2025 |
| Pfizer Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2025 inter alia to consider and approve This is to inform that a meeting of the Board of Directors of the Company is scheduled to be held on Wednesday August 13 2025 inter alia to consider approve and take on record the Unaudited Financial Results of the Company for the quarter ended June 30 2025. Unaudited Financial results for the quarter ended June 30, 2025 (As Per BSE Announcement Dated on: 13.08.2025) | ||
Revenue also saw healthy growth. It was up 7.1% to ₹604 crore from ₹563 crore a year earlier.
Ativan is a common medication used predominantly for anxiety disorders, whereas Pacitane is used for Parkinson’s disease and other neurological conditions.
The agreement, which is discussed up to April and approved by Pfizer's Board of Directors, will be for five years, with discussions ending on 21 February 2025.
Revenue from operations decline marginally by 0.4% YoY at ₹538 crore, as against ₹540 crore in Q3 FY24
At the operating level, EBITDA increased by 60.2%, reaching ₹177.5 Crore in the first quarter of this fiscal year, compared to ₹110.8 Crore in the same quarter last year.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
